hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 05:04:10 - browse：97

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Walensky prepares to leave CDC — and Congress — behind

WSS

Peter Hotez and the public health issue of online harassment

The high cost of giving birth even with insurance

In age of alternative facts, a scholarly course on calling out crap

Novavax promises a turnaround & Lilly roils the obesity market

Congenital heart disease patients face new threat of heart failure

George Santos makes 1st court appearance after pleading not guilty to 13 counts

focus

hotspot

knowledge

Heart attack and stroke risk calculators need revising

AI models in health care face new federal disclosure requirements

BioMarin wins approval for gene therapy to treat hemophilia A

Patients' immediate access to test results puts radiologists in a bind

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CMS should re

Medicare proposal to cover medical devices draws a mixed reaction

SCOTUS to consider access to abortion pill mifepristone

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Patients' immediate access to test results puts radiologists in a bind

knowledge

Radiology is caught between AI's potential and concern for patients

Pfizer plans to depart BIO

STAT letters to the editor on burnt

Radiology is caught between AI's potential and concern for patients

23andMe had bad news about my health. I wish a person had delivered it

Activists slam private health insurers over coverage restrictions

entertainment

hotspot

entertainment

focus